Skip to Content

Atezolizumab Pregnancy and Breastfeeding Warnings

Atezolizumab is also known as: Tecentriq

Atezolizumab Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk. US FDA pregnancy category: Not assigned Risk Summary: -Based on animal studies, this drug impair fertility in females of reproductive potential. -Based on its mechanism of action, this drug can cause harm to a developing fetus.

Animal reproduction studies have not been conducted to evaluate the effect of this drug on reproduction and fetal development. Based on its mechanism of action, it may increase the risk of developing immune-mediated disorders or altering the normal immune response in the fetus. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Atezolizumab Breastfeeding Warnings

Use should be avoided. Excreted into human milk: Data not available Excreted into animal milk: Data not available Comments: -There is no information regarding the presence of this drug in human milk, or the effects on milk production. Because human IgG is excreted in human milk, the potential for absorption and harm to the infant is unknown. -Lactating women should not breastfeed during treatment and for at least 5 months after the last dose.

See references

References for pregnancy information

  1. "Product Information. Tecentriq (atezolizumab)." Genentech, South San Francisco, CA.

References for breastfeeding information

  1. "Product Information. Tecentriq (atezolizumab)." Genentech, South San Francisco, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.